Audited Financial Results for 31st March, 2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Bacil Pharma Ltd reported zero revenue from operations for FY2025-26 compared to Rs. 198.50 lakhs in the previous year, representing a complete revenue collapse. Profit before tax turned negative at Rs. 3.89 lakhs (vs. Rs. 40.76 lakhs profit previously). However, a deferred tax credit of Rs. 56.53 lakhs resulted in a reported profit after tax of Rs. 155.55 lakhs. Other comprehensive income showed a significant loss of Rs. 226.30 lakhs due to fair value changes in financial assets, leading to a total comprehensive loss of Rs. 164.14 lakhs for the year. Total assets stand at Rs. 2739.26 lakhs with cash reserves of Rs. 56.85 lakhs. Auditors issued an unmodified opinion, noting there are no operations currently and management expects to start operations in the future.
The complete cessation of operations is a major red flag despite positive reported PAT due to tax benefits. Shareholders should be extremely cautious as the company has no revenue-generating business, and auditors have highlighted going concern uncertainty without explicitly qualifying their opinion.